ReshmaRangwalaMD
Internal Medicine • Saint Louis, MOHospital Medicine/Hospitalist, Hematology/Oncology
Physician
Are you Dr. Rangwala?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 50 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1 Barnes Jewish Hospital Plz
Saint Louis, MO 63110Phone+1 314-362-1700Fax+1 314-362-9878- Is this information wrong?
Summary
- Dr. Reshma Rangwala, MD is an internist in Saint Louis, Missouri. She is currently licensed to practice medicine in Pennsylvania.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2010 - 2013
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2006 - 2009
University of Cincinnati College of MedicineClass of 2006
Certifications & Licensure
PA State Medical License 2010 - 2016
Publications & Presentations
PubMed
- 58 citationsTisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.David S. Hong, Nicole Concin, Ignace Vergote, Johann S. de Bono, Brian M. Slomovitz, Yvette Drew, Hendrik Tobias Arkenau, Jean Pascal Machiels, James Spicer, Robert H....> ;Clinical Cancer Research. 2020 Mar 15
- 108 citationsTisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trialJohann S. de Bono, Nicole Concin, David S. Hong, Fiona C Thistlethwaite, Jean-Pascal Machiels, Hendrik Tobias Arkenau, Ruth Plummer, Robert H. Jones, Dorte Nielsen, Kr...> ;The Lancet. Oncology. 2019 Mar 1
- 275 citationsCombined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.Dan T. Vogl, Edward A. Stadtmauer, Kay See Tan, Daniel F. Heitjan, Lisa E. Davis, Laura Pontiggia, Reshma Rangwala, Shengfu Piao, Yunyoung C. Chang, Emma C. Scott, Tho...> ;Autophagy. 2014 May 20
- Join now to see all
Press Mentions
Karyopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDSMay 3rd, 2023- Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 ObjectivesJanuary 9th, 2023
- Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of MyelofibrosisNovember 1st, 2022
- Join now to see all
